Form 8-K - Current report:
SEC Accession No. 0001438533-25-000002
Filing Date
2025-01-13
Accepted
2025-01-13 07:30:16
Documents
15
Period of Report
2025-01-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20250113.htm   iXBRL 8-K 33810
2 EX-99.1 aex991_2024q4xearningsprex.htm EX-99.1 47812
6 GRAPHIC image.jpg GRAPHIC 8819
  Complete submission text file 0001438533-25-000002.txt   232985

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20250113.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20250113_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20250113_pre.xml EX-101.PRE 13046
17 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20250113_htm.xml XML 2830
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 25524805
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)